Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuroprotection Following Cardiac Arrest: A Randomized Control Trial of Magnesium
NCT06455514Phase 1Recruiting
- Sponsor
- NYU Langone Health
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of magnesium sulfate in cardiac arrest (SCA) (2 arms), sponsored by NYU Langone Health. Primary endpoints: Proportion of cases where successful randomization occurred at 90 days, Proportion of cases where Magnesium (Mg) or saline bolus was delivered with a goal of <2 h after return of spontaneous circulation (ROSC) at 90 days and 3 more. Started Mar 2025; status: recruiting.
02
Drugs
magnesium sulfate
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on NCT06455514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06455514.